Amicus Therapeutics, Inc. (NASDAQ:FOLD) Stake Lifted by Blue Trust Inc.

Blue Trust Inc. increased its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 1,705.4% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,997 shares of the biopharmaceutical company’s stock after buying an additional 2,831 shares during the quarter. Blue Trust Inc.’s holdings in Amicus Therapeutics were worth $30,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Xponance Inc. grew its stake in Amicus Therapeutics by 5.3% during the 2nd quarter. Xponance Inc. now owns 18,555 shares of the biopharmaceutical company’s stock worth $184,000 after buying an additional 936 shares during the last quarter. Arizona State Retirement System grew its stake in Amicus Therapeutics by 2.6% during the 2nd quarter. Arizona State Retirement System now owns 62,020 shares of the biopharmaceutical company’s stock worth $615,000 after buying an additional 1,577 shares during the last quarter. American International Group Inc. grew its stake in shares of Amicus Therapeutics by 1.3% in the first quarter. American International Group Inc. now owns 143,034 shares of the biopharmaceutical company’s stock worth $1,685,000 after purchasing an additional 1,785 shares in the last quarter. Diversified Trust Co grew its stake in shares of Amicus Therapeutics by 3.8% in the third quarter. Diversified Trust Co now owns 74,501 shares of the biopharmaceutical company’s stock worth $796,000 after purchasing an additional 2,698 shares in the last quarter. Finally, Principal Financial Group Inc. grew its stake in shares of Amicus Therapeutics by 1.1% in the second quarter. Principal Financial Group Inc. now owns 240,813 shares of the biopharmaceutical company’s stock worth $2,389,000 after purchasing an additional 2,737 shares in the last quarter.

Insider Activity

In other news, CEO Bradley L. Campbell sold 7,500 shares of the company’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $11.71, for a total transaction of $87,825.00. Following the completion of the sale, the chief executive officer now directly owns 886,654 shares of the company’s stock, valued at $10,382,718.34. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 2.20% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on FOLD shares. Jefferies Financial Group started coverage on Amicus Therapeutics in a research note on Friday, September 6th. They issued a “buy” rating and a $18.00 price target for the company. Morgan Stanley decreased their price target on Amicus Therapeutics from $19.00 to $18.00 and set an “overweight” rating for the company in a research note on Friday, October 11th. Bank of America increased their price target on Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a research note on Thursday, October 17th. Cantor Fitzgerald reissued an “overweight” rating and issued a $20.00 price target on shares of Amicus Therapeutics in a research note on Friday, September 20th. Finally, StockNews.com cut Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Amicus Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $17.13.

Amicus Therapeutics Stock Performance

Shares of FOLD stock opened at $11.47 on Friday. The stock has a 50-day simple moving average of $11.15 and a 200 day simple moving average of $10.59. Amicus Therapeutics, Inc. has a fifty-two week low of $9.02 and a fifty-two week high of $14.57. The company has a quick ratio of 2.26, a current ratio of 2.75 and a debt-to-equity ratio of 2.93.

Amicus Therapeutics (NASDAQ:FOLD) last announced its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, meeting the consensus estimate of ($0.05). Amicus Therapeutics had a negative return on equity of 41.47% and a negative net margin of 26.23%. The business had revenue of $126.67 million during the quarter, compared to analysts’ expectations of $121.21 million. During the same quarter last year, the business posted ($0.15) earnings per share. The company’s quarterly revenue was up 34.0% on a year-over-year basis. On average, equities analysts predict that Amicus Therapeutics, Inc. will post -0.06 earnings per share for the current year.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.